Evaluation of the Ambuja Cement Foundation Noncommunicable Disease Program in Bathinda District of Punjab, India
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Behavior, Health
- Blood Glucose, High
- Blood Glucose, Low
- Blood Pressure
- Body Weight
- Diabete Type 2
- Lifestyle-related Condition
- Non Communicable Diseases
- Type
- Interventional
- Phase
- Not Applicable
- Design
- Allocation: RandomizedIntervention Model: Sequential AssignmentIntervention Model Description: The study design is stepped wedge randomized cluster trial (4 villages in the first 6 months; additional 4 villages added every 6 months over the next 12 months) - randomized implementation. Staff will visit 10 target villages to screen participants for high NCD risk using CBAC scoring. For adults meeting eligibility criteria, trained enumerators will (1) complete 2 brief surveys (2) measure waist circumference (3) measure blood pressure. The team will schedule a follow-up visit to measure fasting blood glucose. For adults who meet criteria for high-risk for diabetes and hypertension, team will conduct an additional survey on the 2nd day that covers dietary intake & clinical history. Following this, 3 additional follow-up visits will be completed every 6 months for 18 months. Each visit will include: 2 surveys like baseline, measurements of waist circumference, blood pressure, & fasting blood glucose. All participants identified as high risk will be referred to a public hospital.Masking: None (Open Label)Primary Purpose: Health Services Research
Participation Requirements
- Age
- Between 30 years and 125 years
- Gender
- Both males and females
Description
Evaluation visits will be conducted at the participant's home. At baseline, the ACF field team will first administer a screening CRF to all adults in the household to confirm eligibility. For those adults who meet all eligibility criteria, trained enumerators will (1) complete two brief surveys, (2)...
Evaluation visits will be conducted at the participant's home. At baseline, the ACF field team will first administer a screening CRF to all adults in the household to confirm eligibility. For those adults who meet all eligibility criteria, trained enumerators will (1) complete two brief surveys, (2) measure their waist circumference and body weight, and (3) measure their blood pressure using an automatic digital blood pressure machine. The surveys will cover demographics, family history of disease, tobacco and alcohol use, physical activity, and standard clinical symptoms. The field team will then schedule a follow-up visit within the next week to measure fasting blood glucose using a point-of-care device. For those adults who meet criteria for being high-risk for diabetes and hypertension (criteria defined further in the next section), trained enumerators will also administer an additional survey on this second day that covers dietary intake and clinical history including medication use. For high-risk adults, after the baseline visit, three additional follow-up visits will be completed every 6 months for a total duration of 18 months. Each follow-up visit will include: two brief surveys covering the same content summarized above for baseline, as well as measurements of waist circumference, body weight, blood pressure, and fasting blood glucose. We will schedule these visits such that participants are fasting on the day of the visit, thus allowing all visit activities to be completed in 1 day. All surveys will be completed via interviews by trained field enumerators who will enter participant responses into password-protected tablets (Qualtrics offline mobile app). The total population of these 12 villages is 60,701 according to the 2011 Census. We will enroll all adults ?30 years old meeting eligibility criteria, which we estimate will be ~40% of the total population or ~24,280 people. Based on ACF's current programming in 2 other villages in this district, we expect that 40% of those screened (Group 1 participants) will be high-risk (Group 2 participants) or ~9,720 people (~810 per village). For fasting blood glucose, a sample of 12 clusters in a complete stepped-wedge cluster-randomized design with 4 time periods (including the baseline), 3 steps, 4 clusters switching from control to treatment at each step, and an average of 500 participants per cluster with an average of 125 participants per cluster per time period (for a total sample size of 6000 subjects) achieves 90% power to detect a difference between means of 0.32 mmol/L (4% of anticipated mean baseline level). The test statistic used is the two-sided Wald Z-Test. The ICC is 0.010, and the significance level of the test is 0.050. Given that we expect to enroll near to 9000 subjects, we are exceptionally well powered to detect significant effects in this evaluation even if there is loss to follow up.
Tracking Information
- NCT #
- NCT04827615
- Collaborators
- Ambuja Cement Foundation
- Investigators
- Not Provided